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Background: In order to avoid separate injections, admixtures of drugs are frequently 
used in palliative care settings. There are different factors that can influence the 
compatibility and stability of the mixture: drug type, concentration, solvent, container, 
temperature and light. There are some mixtures of drugs with proven stability, but there 
is lack of evidence about the stability and compatibility of the combination of hyoscine 
N-butyl bromide and furosemide. 
 
Purpose: To evaluate the compatibility and stability of three admixtures of hyoscine N-
butyl bromide and furosemide at two different temperatures (25ºC and 37ºC). The 
concentrations of the admixtures are: 2.0 mg/ml-2.0 mg/ml; 1.0 mg/ml-0.6 mg/ml; 0.6 
mg/ml-0.6 mg/ml, in NaCl 0.9% stored in elastomeric infusors protected from light. 
  
Material and method: The samples were prepared and diluted in NaCl 0.9% in 
elastomeric infusor in triplicate to obtain six different conditions of concentration and/or 
temperature of storage (concentration : 2.0 mg/ml - 2.0 mg/ml, 1.0 mg/ml – 0.6 mg/ml 
and 0.6 mg/ml – 0.6 mg/ml of hyoscine N-butyl bromide and furosemide respectively; 
temperature of storage 25ºC and 37ºC).  
The concentration of each constituent drug into different mixtures was periodically 
determined using a HPLC-UV method. The drugs were chromatographed on a C18 
reverse phase column; the mobile phase was acetonitrile-water 80:20 (v/v); flow rate 1.5 
ml/min. Hyoscine N-butyl bromide and furosemide concentrations were determined at 
220 nm by interpolation from the calibration curves prepared at (0, 1, 2, 3, 7, 11, 15) 
days from the standards. Statgraphics centurion XVI program has been used to data 
treatment. 
 
Results and discussion: The stability of the admixtures diluted in NaCl 0.9% are as 
follow: hyoscine N-butyl bromide -furosemide (2.0 mg/ml-2.0 mg/ml) is stable 
(retained >95% of their initial concentration) two days at 25ºC and 37ºC; (1.0 mg/ml-
0.6 mg/ml) is stable eight days at 25ºC and two days at 37ºC; (0.6 mg/ml-0.6 mg/ml) is 
stable twelve days at 25ºC and three days at 37ºC. 
 
Conclusion: The admixture of hyoscine N-butyl bromide and furosemide in NaCl 0.9% 
in elastomeric infusor can be safely used in palliative care for at least two days. Lower 
concentration of the admixture can be prepared in advance and stored at room 
temperature, but the infusion cannot be longer than tree days. 
 
